Clinical review of muscle-specific tyrosine kinase-antibody positive myasthenia gravis

Journal of Clinical Neuromuscular Disease

Volumn 8, Issue 4, 2007, Pages 217-224

  Wolfe, Gil I ^a   Trivedi, Jaya R ^a   Oh, Shin J ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

Muscle specific tyrosine kinase; Myasthenia gravis; Phenotype; Treatment

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; RITUXIMAB;

ANTIBODY SPECIFICITY; BULBAR PARALYSIS; DEMOGRAPHY; ELECTROMYOGRAPHY; HUMAN; LIMB WEAKNESS; MUSCLE INNERVATION; MYASTHENIA GRAVIS; NERVE STIMULATION; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SERODIAGNOSIS; THYMECTOMY; TREATMENT RESPONSE;

EID: 34447304342     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e318137a24b     Document Type: Review

References (37)

1. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Med. 2001;7:365-368.
2. Selcen D, Fukuda T, Shen X-M, et al. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology. 2004;62:1945-1950.
3. Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol. 2005;57:289-293.
4. Jha S, Xu K, Maruta T, et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol. 2006;175:107-117.
5. Lee JY, Sung JJ, Cho JY, et al. MuSK antibody-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci. 2006;13:353-355.
6. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978-1980.
7. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304-2311.
8. Bartoccioni E, Scuderi F, Minicuci GM, et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology. 2006;67:505-507.
9. Zhou L, McConville J, Chaudhry V, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004;30:55-60.
10. Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophys. 2005;116:2065-2068.
11. Caress JB, Hunt CH, Batish SD. Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol. 2005;62:1002-1003.
12. Hanisch F, Eger K, Zierz S. MuSK-antibody positive pure ocular myasthenia gravis. J Neurol. 2006;253:659-660.
13. Padua L, Tonali P, Aprile I, et al. Seronegative myasthenia gravis: comparison of neurophysiological picture in MuSK+ and MuSK- patients. Eur J Neurol. 2006;13:273-276.
14. Nemoto Y, Kuwabara S, Misawa S, et al. Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005;76:714-718.
15. Farrugia ME, Robson MD, Clover L, et al. MRI and clinical studies of facial and bulbar involvement in MuSK antibody-associated myasthenia gravis. Brain. 2006;129:1481-1492.
16. Pasnoor M, Wolfe G, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis (abstract). Neurology. 2007;68:A299.
17. Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK- vs anti-AchR-positive and seronegative myasthenia gravis. Neurology. 2007;68:609-611.
18. Hatanaka Y, Hemmi S, Morgan MB, et al. Non-responsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology. 2005;65:1508-1509.
19. Punga AR, Flink R, Askmark H, et al. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve. 2006;34:111-115.
20. Oh SJ, Hatanaka Y, Hemmi S, et al. Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis. Muscle Nerve. 2006;33:500-504.
21. Kuwabara S, Nemoto Y, Misawa S, et al. Anti-MuSK-positive myasthenia gravis: neuromuscular transmission failure in facial and limb muscles. Acta Neurol Scand. 2007;115:126-128.
22. Farrugia ME, Kennett RP, Newsom-Davis J, et al. Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve. 2006;33:568-570.
23. Farrugia ME, Kennett RP, Hilton-Jones D, et al. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clinical Neurophys. 2007;118:269-277.
24. Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005;64:536-538.
25. Saka E, Topcuoglu MA, Akkaya B, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005;65:782-783.
26. Leite MI, Ströbel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005;57:444-448.
27. Takahashi H, Kawaguchi N, Nemoto Y, et al. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis. J Neurol Sci. 2006;247:239-241.
28. Lavrnic D, Losen M, Vujic A, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry. 2005;76:1099-1102.
29. Sanders D, Massey J, Juel V. MuSK antibody positive myasthenia gravis: response to treatment in 31 patients. Neurology (abstract). 2007;68:A299.
30. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol. 2003;53:29-34.
31. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006;33:575-580.
32. Lin PT, Martin BA, Weinacker AB, et al. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve. 2006;33:433-435.
33. Diaz-Manera J, Rajas-Garcia R, Juarez C, et al. Are immunosuppressors as effective in MuSK+ MG as in AChR+ MG patients? Evaluation of 150 myasthenic patients treated with the same protocol (abstract). Neurology. 2007;68:A300.
34. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55:580-584.
35. Yeh J-H, Chen W-H, Chiu H-C, et al. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology. 2004;62:2131-2132.
36. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol. 2005;12:413-418.
37. Niks EH, Kuks JBM, Verschuuren JJGM. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. J Neurol Neurosurg Psychiatry. 2007;78:417-418.